Helius Medical Technologies, Inc. HSDT
We take great care to ensure that the data presented and summarized in this overview for HELIUS MEDICAL TECHNOLOGIES, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in HSDT
Top Purchases
Top Sells
About HSDT
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
Insider Transactions at HSDT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 14
2023
|
Dane Andreeff President and CEO |
BUY
Open market or private purchase
|
Indirect |
5,000
+13.35%
|
$40,000
$8.1 P/Share
|
|
Dec 01
2023
|
Dane Andreeff President and CEO |
BUY
Open market or private purchase
|
Indirect |
2,006
+6.84%
|
$12,036
$6.45 P/Share
|
|
Nov 30
2023
|
Dane Andreeff President and CEO |
BUY
Open market or private purchase
|
Indirect |
2,000
+7.34%
|
$12,000
$6.37 P/Share
|
|
Aug 30
2023
|
Dane Andreeff President and CEO |
BUY
Open market or private purchase
|
Indirect |
5,000
+17.76%
|
$35,000
$7.64 P/Share
|
|
Aug 28
2023
|
Dane Andreeff President and CEO |
BUY
Open market or private purchase
|
Indirect |
5,078
+21.92%
|
$30,468
$6.37 P/Share
|
|
May 24
2023
|
Blane Walter |
BUY
Grant, award, or other acquisition
|
Direct |
83,054
+47.05%
|
-
|
|
May 24
2023
|
Paul Buckman |
BUY
Grant, award, or other acquisition
|
Direct |
83,054
+48.04%
|
-
|
|
May 24
2023
|
Sherrie L Perkins |
BUY
Grant, award, or other acquisition
|
Direct |
83,054
+47.98%
|
-
|
|
May 24
2023
|
Edward M Straw |
BUY
Grant, award, or other acquisition
|
Direct |
83,054
+47.96%
|
-
|
|
Dec 16
2022
|
Dane Andreeff President and CEO |
BUY
Open market or private purchase
|
Indirect |
80,041
+11.19%
|
$0
$0.25 P/Share
|
|
Nov 23
2022
|
Dane Andreeff President and CEO |
BUY
Open market or private purchase
|
Indirect |
89,300
+14.01%
|
$0
$0.31 P/Share
|
|
Nov 22
2022
|
Dane Andreeff President and CEO |
BUY
Open market or private purchase
|
Indirect |
10,000
+4.38%
|
$0
$0.28 P/Share
|
|
Nov 17
2022
|
Dane Andreeff President and CEO |
BUY
Open market or private purchase
|
Indirect |
106,541
+19.02%
|
$0
$0.34 P/Share
|
|
Nov 16
2022
|
Dane Andreeff President and CEO |
BUY
Open market or private purchase
|
Indirect |
10,000
+6.07%
|
$0
$0.32 P/Share
|
|
Sep 13
2022
|
Dane Andreeff President and CEO |
BUY
Open market or private purchase
|
Indirect |
150,000
+38.6%
|
$0
$0.53 P/Share
|
|
Sep 12
2022
|
Dane Andreeff President and CEO |
BUY
Open market or private purchase
|
Indirect |
8,868
+3.16%
|
$0
$0.54 P/Share
|
|
Aug 25
2022
|
Dane Andreeff President and CEO |
BUY
Open market or private purchase
|
Indirect |
74,800
+22.14%
|
$0
$0.63 P/Share
|
|
Aug 24
2022
|
Dane Andreeff President and CEO |
BUY
Open market or private purchase
|
Indirect |
25,200
+11.81%
|
$0
$0.65 P/Share
|
|
May 23
2022
|
Paul Buckman |
BUY
Grant, award, or other acquisition
|
Direct |
6,049
+47.19%
|
-
|
|
May 23
2022
|
Edward M Straw |
BUY
Grant, award, or other acquisition
|
Direct |
6,049
+46.15%
|
-
|
Last 12 Months Summary
| Open market or private purchase | 5K shares |
|---|